This Week’s Biopharma News: Big Moves in Bispecifics - Summary - MDSpire

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min

Share

Objective:

To summarize recent advancements and approvals in biopharmaceuticals, particularly focusing on bispecific antibodies and other innovative therapies.

Key Findings:
  • Ivonescimab improved overall survival by 34% compared to tislelizumab plus chemotherapy.
  • Imdylltra showed a 40% reduction in mortality compared to standard chemotherapy in small cell lung cancer.
  • Daretabart has shown promising survival rates in pediatric patients with high-risk neuroblastoma.
  • The collaboration between Dark Horse and Altruist aims to streamline biologics development in China.
  • Pfizer's deal with Innovent includes significant milestone payments and co-development opportunities.
  • NewLimit's funding will support the transition of its aging reprogramming therapy into human trials.
  • Servier's acquisition of Edgewise supports its strategy in rare neuromuscular disorders.
Interpretation:

The advancements in bispecific antibodies and other therapies highlight significant progress in treating various cancers and rare diseases.

Limitations:
  • The article does not provide detailed information on the long-term efficacy and safety of the therapies discussed.
  • No patient demographic data or specific trial methodologies are included.
Conclusion:

The biopharma sector is witnessing substantial developments, particularly in bispecific therapies and innovative treatments for challenging conditions.

Original Source(s)

This Week’s Biopharma News: Big Moves in Bispecifics

  • June 9, 2026

Related Content

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min
Case Study: BRCA Mutation Led To Early Detection of Pre-Ovarian Cancer Condition

A 59-year-old woman was referred to Nicole Gaulin, MD, a gynecologic oncologist at Roswell Park Comprehensive Cancer Center, after learning she had a BRCA2 mutation linked with both breast cancer in a cousin and colon cancer in her father.

  • June 24, 2026

  • 1 min
The Secrets of the Gut

Going beyond the gut: why microbiome testing is the next big thing in drug development